Cells (May 2023)

Next-Generation Boron Drugs and Rational Translational Studies Driving the Revival of BNCT

  • Danushka S. Seneviratne,
  • Omran Saifi,
  • Yuri Mackeyev,
  • Timothy Malouff,
  • Sunil Krishnan

DOI
https://doi.org/10.3390/cells12101398
Journal volume & issue
Vol. 12, no. 10
p. 1398

Abstract

Read online

BNCT is a high-linear-energy transfer therapy that facilitates tumor-directed radiation delivery while largely sparing adjacent normal tissues through the biological targeting of boron compounds to tumor cells. Tumor-specific accumulation of boron with limited accretion in normal cells is the crux of successful BNCT delivery. Given this, developing novel boronated compounds with high selectivity, ease of delivery, and large boron payloads remains an area of active investigation. Furthermore, there is growing interest in exploring the immunogenic potential of BNCT. In this review, we discuss the basic radiobiological and physical aspects of BNCT, traditional and next-generation boron compounds, as well as translational studies exploring the clinical applicability of BNCT. Additionally, we delve into the immunomodulatory potential of BNCT in the era of novel boron agents and examine innovative avenues for exploiting the immunogenicity of BNCT to improve outcomes in difficult-to-treat malignancies.

Keywords